STAHL NEIL has filed 35 insider transactions across 1 company since August 2023.
Most recent transaction: a tax payment of 304 shares of REGENERON PHARMACEUTICALS, INC. ($REGN) on December 16, 2024.
Activity breakdown: 0 open-market purchases and 16 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 16, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 304 | $730.81 | 59,283.0000 | 135,300,000 | 0.51% | 0.00% |
| Dec. 9, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 466 | $787.00 | 59,587.0000 | 135,300,000 | 0.78% | 0.00% |
| Aug. 13, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | G | Common Stock | 500 | $0.00 | 60,053.0000 | 134,800,000 | 0.83% | 0.00% |
| Aug. 8, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 100 | $1081.83 | 66,550.0000 | 134,800,000 | 0.15% | 0.00% |
| Aug. 8, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 200 | $1082.69 | 66,350.0000 | 134,800,000 | 0.30% | 0.00% |
| Aug. 8, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 1006 | $1083.76 | 65,344.0000 | 134,800,000 | 1.52% | 0.00% |
| Aug. 8, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 1883 | $1084.61 | 63,461.0000 | 134,800,000 | 2.88% | 0.00% |
| Aug. 8, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 1708 | $1085.01 | 61,753.0000 | 134,800,000 | 2.69% | 0.00% |
| Aug. 8, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 300 | $1086.15 | 61,453.0000 | 134,800,000 | 0.49% | 0.00% |
| Aug. 12, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | G | Common Stock | 900 | $0.00 | 60,553.0000 | 134,800,000 | 1.46% | 0.00% |
| Aug. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | M | Common Stock | 23638 | $555.67 | 85,091.0000 | 134,800,000 | 38.47% | 0.02% |
| Aug. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 18441 | $1093.49 | 66,650.0000 | 134,800,000 | 21.67% | 0.01% |
| Aug. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | M | Non-Qualified Stock Option (right to buy) | 23638 | $0.00 | 45,000.0000 | 134,800,000 | 34.44% | 0.02% |
| Feb. 26, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | G | Common Stock | 1020 | $0.00 | 61,438.0000 | 133,100,000 | 1.63% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 100 | $947.34 | 70,395.0000 | 133,100,000 | 0.14% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 1894 | $948.69 | 68,501.0000 | 133,100,000 | 2.69% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 601 | $949.45 | 67,900.0000 | 133,100,000 | 0.88% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 3127 | $950.43 | 64,773.0000 | 133,100,000 | 4.61% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 1237 | $951.49 | 63,536.0000 | 133,100,000 | 1.91% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 1059 | $952.49 | 62,477.0000 | 133,100,000 | 1.67% | 0.00% |
| Feb. 7, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 19 | $953.00 | 62,458.0000 | 133,100,000 | 0.03% | 0.00% |
| Feb. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | M | Common Stock | 30750 | $399.66 | 93,208.0000 | 133,100,000 | 49.23% | 0.02% |
| Feb. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 22713 | $956.65 | 70,495.0000 | 133,100,000 | 24.37% | 0.02% |
| Feb. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | M | Non-Qualified Stock Option (right to buy) | 30750 | $0.00 | 0.0000 | 133,100,000 | 100.00% | 0.02% |
| Dec. 8, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 809 | $843.79 | 62,330.0000 | 130,400,000 | 1.28% | 0.00% |
| Dec. 8, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | A | Common Stock | 853 | $0.00 | 63,183.0000 | 130,400,000 | 1.37% | 0.00% |
| Dec. 11, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 725 | $844.09 | 62,458.0000 | 130,400,000 | 1.15% | 0.00% |
| Dec. 8, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | A | Non-Qualified Stock Option (right to buy) | 3059 | $0.00 | 3,059.0000 | 130,400,000 | 9999.99% | 0.00% |
| Nov. 10, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | G | Common Stock | 400 | $0.00 | 63,139.0000 | 130,400,000 | 0.63% | 0.00% |
| Aug. 21, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | M | Common Stock | 50000 | $399.66 | 113,539.0000 | 130,400,000 | 78.69% | 0.04% |
| Aug. 21, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | F | Common Stock | 38335 | $833.39 | 75,204.0000 | 130,400,000 | 33.76% | 0.03% |
| Aug. 22, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 6309 | $840.53 | 68,895.0000 | 130,400,000 | 8.39% | 0.00% |
| Aug. 22, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 4574 | $841.41 | 64,321.0000 | 130,400,000 | 6.64% | 0.00% |
| Aug. 22, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | S | Common Stock | 782 | $842.16 | 63,539.0000 | 130,400,000 | 1.22% | 0.00% |
| Aug. 21, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | STAHL NEIL | EVP Research and Development | M | Non-Qualified Stock Option (right to buy) | 50000 | $0.00 | 30,750.0000 | 130,400,000 | 61.92% | 0.04% |